Thank you for your question and for providing photos. When it comes to treating acne scars—particularly rolling scars, boxcar scars, and icepick scars—a multimodal approach is often most effective. Here's how each of the treatments you mentioned fits into that landscape: Verteporfin Verteporfin is traditionally used in ophthalmology but has recently gained interest for dermatologic use due to its anti-fibrotic and anti-scarring potential. Some early studies suggest it may inhibit the fibrotic response in scar tissue, but its use for acne scars is still experimental and not yet widely adopted in clinical practice. Dermaclae Dermaclae is marketed as a topical growth factor and regenerative therapy. While it may help improve skin texture and tone, its impact on deeper acne scars (especially icepick or boxcar types) is likely limited unless combined with other modalities like microneedling or laser. Renuva Renuva is an adipose matrix injectable designed to restore volume and stimulate tissue regeneration. It can be particularly helpful in treating rolling scars, which are caused by volume loss and tethering beneath the skin. Renuva essentially encourages your own body to regenerate fat in the treated area. Can They Be Combined? Theoretically, yes, these treatments could be combined, but careful planning and sequencing would be essential: Renuva could be used to restore volume and improve contour, particularly for rolling scars. Verteporfin may serve as a supportive treatment to limit fibrosis if used with appropriate guidance. Dermaclae might complement the regenerative process, especially if used post-procedure (e.g., after microneedling or laser). However, these combinations are not standard practice yet, and there is limited clinical data on using all three together. Treatment success often depends on individual scar type, skin condition, and overall treatment goals. A layered, customized plan—sometimes involving resurfacing procedures or subcision—is usually required for meaningful improvement in atrophic acne scars.